Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis

Int J Infect Dis. 2016 Aug:49:129-33. doi: 10.1016/j.ijid.2016.06.015. Epub 2016 Jun 21.

Abstract

The Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with life-threatening severe illnesses and a mortality rate of approximately 35%, particularly in patients with underlying comorbidities. A systematic analysis of 637 MERS-CoV cases suggests that diabetes and hypertension are equally prevalent in approximately 50% of the patients. Cardiac diseases are present in 30% and obesity in 16% of the cases. These conditions down-regulate the synthesis of proinflammatory cytokines and impair the host's innate and humoral immune systems. In conclusion, protection against MERS-CoV and other respiratory infections can be improved if public health vaccination strategies are tailored to target persons with chronic disorders.

Keywords: Cardiovascular diseases; Diabetes mellitus; Middle East respiratory syndrome coronavirus (MERS-CoV); Obesity; Systematic review.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Comorbidity
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / etiology
  • Humans
  • Male
  • Middle East Respiratory Syndrome Coronavirus / isolation & purification*
  • Prevalence